A pre-post quasi-experimental study of the impact of TDM-guided aggressive pharmacokinetic/pharmacodynamic target attainment of continuous infusion ceftolozane/tazobactam monotherapy in treating severe Pseudomonas aeruginosa infections: a strategy useful for raising the bar?
Journal of Antimicrobial Chemotherapy · 2025
DOI: 10.1093/jac/dkaf098 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Milo Gatti und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy. Hauptthemen laut MEDLINE: Pseudomonas Infections, Cephalosporins, Pseudomonas aeruginosa, Anti-Bacterial Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NextGeneration EU-MUR PNRR Extended Partnership.
Abstract (Originalsprache)
Objectives
To assess the clinical usefulness of a therapeutic drug monitoring (TDM)-guided strategy for attaining an aggressive pharmacokinetic/pharmacodynamic (PK/PD) target of continuous infusion (CI) ceftolozane/tazobactam monotherapy in patients having Pseudomonas aeruginosa infections.
Methods
We performed a pre-post quasi-experimental study including adult patients with documented P. aeruginosa bacteraemia and/or pneumonia who were treated with CI ceftolozane/tazobactam monotherapy tailored by means of a TDM-guided strategy in the period 1 November 2023 to 31 July 2024 (post-intervention phase) compared with patients receiving standard management with CI ceftolozane/tazobactam monotherapy in the period 1 April 2022 to 31 October 2023 (pre-intervention phase). Clinical outcomes were compared between pre- and post-intervention phase. Univariate and multivariate analyses were performed for identifying variables associated with microbiological failure.
Results
Eighty-five patients (48 in pre- and 37 in post-intervention phase) were included. Demographics and clinical features were similar in both groups. No significant difference emerged between groups in terms of microbiological eradication (P = 0.10), 30 day resistance to ceftolozane/tazobactam (P = 0.37), clinical cure (P = 0.26) and 30 day mortality rate (P = 0.79). All patients in the post-intervention phase attained an optimal PK/PD target, allowing the use of a lower ceftolozane/tazobactam CI daily dosing regimen compared with the pre-intervention phase (3.0 g/1.5 g versus 6.0 g/3.0 g; P = 0.06). The only independent predictors of microbiological failure were difficult-to-treat resistant P. aeruginosa isolates in the pre-intervention group (OR 6.99; 95% CI 1.34–36.55), and a ratio of partial pressure of arterial oxygen to fraction of oxygen in the inhaled air (Pao2/Fio2 ratio) <200 in the post-intervention group (OR 18.00; 95% CI 1.86–174.22).
Conclusions
Our TDM-guided strategy of CI ceftolozane/tazobactam was cost-effective in attaining an aggressive PK/PD target of ceftolozane against susceptible P. aeruginosa strains with lower than standard daily doses without compromising efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy.
- Clinical Pharmacology Unit, Department for Integrated Infectious Risk Management, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Massarenti 9, Bologna 40138, Italy.
- Infectious Diseases Unit, Department for Integrated Infectious Risk Management, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
- Anesthesia and Intensive Care Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
- Division of Anesthesiology, Department of Anesthesia and Intensive Care, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
- Operative Unit of Microbiology, Department for Integrated Infectious Risk Management, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
ORCID-Profile: Milo Gatti, Matteo Rinaldi, Cecilia Bonazzetti, Federico Pea
Förderung
- NextGeneration EU-MUR PNRR Extended Partnership
Zitieren
APA
Gatti, M., Rinaldi, M., Bonazzetti, C., Siniscalchi, A., Tonetti, T., Ambretti, S., Giannella, M., Viale, P., & Pea, F. (2025). A pre-post quasi-experimental study of the impact of TDM-guided aggressive pharmacokinetic/pharmacodynamic target attainment of continuous infusion ceftolozane/tazobactam monotherapy in treating severe Pseudomonas aeruginosa infections: a strategy useful for raising the bar?. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf098
Vancouver
Gatti M, Rinaldi M, Bonazzetti C, Siniscalchi A, Tonetti T, Ambretti S, et al. A pre-post quasi-experimental study of the impact of TDM-guided aggressive pharmacokinetic/pharmacodynamic target attainment of continuous infusion ceftolozane/tazobactam monotherapy in treating severe Pseudomonas aeruginosa infections: a strategy useful for raising the bar?. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkaf098
BibTeX
@article{Gatti2025,
author = {Gatti, Milo and Rinaldi, Matteo and Bonazzetti, Cecilia and Siniscalchi, Antonio and Tonetti, Tommaso and Ambretti, Simone and Giannella, Maddalena and Viale, Pierluigi and Pea, Federico},
title = {A pre-post quasi-experimental study of the impact of TDM-guided aggressive pharmacokinetic/pharmacodynamic target attainment of continuous infusion ceftolozane/tazobactam monotherapy in treating severe Pseudomonas aeruginosa infections: a strategy useful for raising the bar?},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2025},
doi = {10.1093/jac/dkaf098}
}
EUVIMED